MedTrace Logo

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

NCT04325880 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2021-11-23

No results posted yet for this study

Summary

The primary objective of this prospective, single-centre randomized controlled trial is to assess the efficacy of three different drugs in treatment of ureteral stents related symptoms (Beta 3 adrenergic receptor agonist; Mirabegron 50mg) vs. (Alpha 1 adrenergic receptor antagonist; Tamsulosin 0.4mg) vs. (Anticholinergic; Solifenacin 10 mg) using validated symptoms questionnaires.

In addition, adverse events of the utilized medications will be monitored during study period as a secondary objective.

Conditions

  • Ureteral Stent
  • Stent Related Symptoms

Interventions

DRUG

Mirabegron 50 MG

Patients in this arm will receive Mirabegrone 50 MG once daily

DRUG

Tamsulosin

Patients in this arm will receive Tamsulosin o.4 MG once daily

DRUG

Solifenacin Succinate 10 MG

Patients in this arm will receive Solifenacin Succinate 10 MG once daily

DRUG

Placebo oral tablet

Patients in this arm will receive placebo oral tablet once daily

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Amr A Elsawy · Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-06-01
Completion
2022-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04325880 on ClinicalTrials.gov